(Q44801887)

6 December 2017

title

Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant (English)

1 reference

6 December 2017

T L Parker

1

1 reference

6 December 2017

D L Cooper

series ordinal

2

1 reference

6 December 2017

S E Seropian

series ordinal

3

1 reference

6 December 2017

J L Bolognia

series ordinal

4

1 reference

6 December 2017

language of work or name

English

0 references

publication date

19 November 2012

1 reference

Bone Marrow Transplantation

6 December 2017

published in

1 reference

6 December 2017

volume

48

1 reference

6 December 2017

issue

5

1 reference

6 December 2017

page(s)

646-650

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2012.218

6 December 2017

exact match

0 references

cites work

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

7 January 2021

Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

7 January 2021

Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

7 January 2021

Toxic erythema of chemotherapy: a useful clinical term

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

7 January 2021

The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

7 January 2021

https://api.crossref.org/works/10.1038%2FBMT.2012.218

1 reference

7 January 2021

Chemotherapy-induced acral erythema (CIAE) with bullous reaction

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

7 January 2021

Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

7 January 2021

Distinctive acral erythema occurring during therapy for severe myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.218

7 January 2021

Identifiers

DOI

10.1038/BMT.2012.218

1 reference

6 December 2017

1 reference